Literature DB >> 1583555

Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials.

W J Curran1, C B Scott, J Horton, J S Nelson, A S Weinstein, D F Nelson, A J Fischbach, C H Chang, M Rotman, S O Asbell.   

Abstract

103 patients with the diagnosis of AAF were identified from the RT/BCNU arms of 3 RTOG malignant glioma trials. Pre-treatment tumor size was less than 5 cm for 48% and greater than or equal to 5 cm for 52%, and tumor sites were frontal lobe in 55%, temporal in 25%, and parietal in 16%. Surgery consisted of biopsy for 30%, partial resection for 56%, and total resection for 14%. Extent of surgery correlated with age, with 81% of patients less than 40 undergoing partial/total resection vs. 60% of those over 40 (P = 0.019). The median survival time (MST) of patients undergoing partial/total resection was 49 mo., vs. 18 mo. for those biopsied only (P = 0.002). Patients with frontal location had longer MST than those with non-frontal lesions (MST: 49 vs. 25 mo., P = 0.047), while no survival difference was apparent by univariate analysis of tumor size. Multivariate analysis demonstrated that only younger age, frontal location, and smaller tumor size correlated significantly with extended survival. Extent of surgery was not predictive. The close correlation between young age and extensive surgery obscures the survival advantage for greater surgery seen with univariate analysis. Smaller tumor size and frontal location favorably influence outcome even when adjusted by age.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1583555     DOI: 10.1007/bf00172709

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  32 in total

1.  Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas.

Authors:  M Ammirati; N Vick; Y L Liao; I Ciric; M Mikhael
Journal:  Neurosurgery       Date:  1987-08       Impact factor: 4.654

2.  Surgical resection of malignant brain tumors: who benefits?

Authors:  M Salcman
Journal:  Oncology (Williston Park)       Date:  1988-08       Impact factor: 2.990

3.  Glioblastoma multiforme: its treatment and some factors effecting survival.

Authors:  R Jelsma; P C Bucy
Journal:  Arch Neurol       Date:  1969-02

4.  A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study.

Authors:  D F Nelson; M Diener-West; A S Weinstein; D Schoenfeld; J S Nelson; W T Sause; C H Chang; R Goodman; S Carabell
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-10       Impact factor: 7.038

5.  Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery. A Southwest Oncology Group Report.

Authors:  H J Eyre; J M Quagliana; J R Eltringham; J Frank; R M O'Bryan; B McDonald; S E Rivkin
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

6.  Misonidazole combined with hyperfractionation in the management of malignant glioma.

Authors:  D S Fulton; R C Urtasun; K H Shin; P H Geggie; H Thomas; P J Muller; J Moody; H Tanasichuk; B Mielke; E Johnson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-09       Impact factor: 7.038

7.  Evaluation of CCNU, VM-26 plus CCNU, and procarbazine in supratentorial brain gliomas. Final evaluation of a randomized study. European Organization for Research on Treatment of Cancer (EORTC) Brain Tumor Group.

Authors: 
Journal:  J Neurosurg       Date:  1981-07       Impact factor: 5.115

8.  Misonidazole in radiotherapy of supratentorial malignant brain gliomas in adult patients: a randomized double-blind study.

Authors: 
Journal:  Eur J Cancer Clin Oncol       Date:  1983-01

9.  Survival and prognosis of patients with astrocytoma with atypical or anaplastic features.

Authors:  D F Nelson; J S Nelson; D R Davis; C H Chang; T W Griffin; T F Pajak
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  17 in total

Review 1.  Extent of resection as a prognostic variable in the treatment of gliomas.

Authors:  K R Hess
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

2.  The benefit of surgical resection in recurrent glioblastoma.

Authors:  Michael A Vogelbaum
Journal:  Neuro Oncol       Date:  2016-02-10       Impact factor: 12.300

3.  Surgical management of newly diagnosed glioblastoma in adults: role of cytoreductive surgery.

Authors:  Timothy C Ryken; Bruce Frankel; Terrance Julien; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2008-08-20       Impact factor: 4.130

4.  Towards a genomic definition of completeness of resection?

Authors:  Michael A Vogelbaum
Journal:  Neuro Oncol       Date:  2014-01       Impact factor: 12.300

Review 5.  Operative techniques for gliomas and the value of extent of resection.

Authors:  Nader Sanai; Mitchel S Berger
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 6.  Basic surgical techniques in the resection of malignant gliomas.

Authors:  S A Toms; D Z Ferson; R Sawaya
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

Review 7.  Maximizing safe resection of low- and high-grade glioma.

Authors:  Shawn L Hervey-Jumper; Mitchel S Berger
Journal:  J Neurooncol       Date:  2016-05-12       Impact factor: 4.130

8.  Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience.

Authors:  Maria Teresa Solomon; Nederlay Miranda; Eugenia Jorrín; Ivonne Chon; Jorge Juan Marinello; José Alert; Patricia Lorenzo-Luaces; Tania Crombet
Journal:  Cancer Biol Ther       Date:  2014-02-12       Impact factor: 4.742

9.  Validation of the Medical Research Council and a newly developed prognostic index in patients with malignant glioma: how useful are prognostic indices in routine clinical practice?

Authors:  Fadime Akman; Rachel A Cooper; Mehmet Sen; Yildiray Tanriver; Süleyman Kentli
Journal:  J Neurooncol       Date:  2002-08       Impact factor: 4.130

10.  Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab.

Authors:  Jidong Hong; Yuping Peng; Yuping Liao; Wuzhong Jiang; Rui Wei; Lei Huo; Zaide Han; Chaojun Duan; Meizuo Zhong
Journal:  Exp Ther Med       Date:  2012-04-19       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.